questions, page-12

$400K to $500K cash based on prev quarter's cash spend is indisputable and the fact that the new SLACFs via the rights issue or equiv. are below the 30c with little demand.

I would've brought an options deal forward, but no, they need the money so they ultimately may not be questioned by the ASX as a going concern IMO as they have in the past.

Skin of their teeth without an ASX enquiry.

Good luck with the HIV trials.

"Dr Nina Petrovna Golovkina of the Skvortsova Stepanova Psychiatric Hospital made it clear to shareholders when she
addressed the EGM in September 2007, that her hospital would be using Ropren to treat alcoholics, drug addicts and patients with neuro-degenerative disorders, as soon as it was available."

Who is Nina?

http://www.stocknessmonster.com/news-item?S=SLA&E=ASX&N=290829